Background As of 2012, approximately 4
general was estimated to account for more than 800,000 annual hospital admissions and 35,000 mortality cases in the US [2, 3] . The incidence and prevalence of arrhythmias are significantly age related and vary by arrhythmia subtype. Specifically, over half of CA cases were atrial fibrillation (AF), which currently affects more than 2.2 million individuals; approximately 70 % of whom are aged between 65 and 85 years [1] . The incidence of AF varies from 11 per 1000 persons for those aged 65-69 years to almost 60 per 1,000 persons for those aged 80 years and older [4] . In addition, the prevalence of AF in the general population is approximately 0.5-1 % [5] . The number of people with AF is anticipated to rise to approximately 5.6 million by 2050 [1] .
Relevant risk factors for CA include age and family history [5] [6] [7] . In addition, several studies have demonstrated that multiple chronic conditions including hypertension, diabetes mellitus, congestive heart failure, and valvular heart disease place patients at an increased risk to develop CA [8] [9] [10] . Patients with chronic CAs, particularly after atrial flutter or rapid episodes of ventricular dysrhythmias are more likely to experience dizziness, fatigue, dyspnea, palpitations, and severe problems with exercising and thus have a lower quality of life [11, 12] .
Several options are available for the management of CA, including pharmacotherapy (i.e., anti-arrhythmic agents), electrical therapy, and surgical procedures. Pharmacological agents can be classified as having five main types of anti-arrhythmic effects, aimed at helping control heart rate and rhythm. These treatments stabilize CA by either suppressing the frequency of generation of electrical impulses at the sinoatrial node or at an ectopic site, or by slowing and regulating the electrical velocity of conduction within the heart [1] . Drug mechanisms for arrhythmia can work on multiple ion channels including: sodium, calcium, and potassium. The effects on sodium channels can be subdivided into three characterized groups: (1) fast (\300 ms), (2) medium (200-1,500 ms), and (3) slow ([1,500 ms) time constraints for recovery from blockage [13] . Sodium channel blockers include quinidine, lidocaine, propranolol, and several others. Verapamil and diltiazem are primarily calcium channel blockers. Finally, amiodarone, sotalol, and bretylium are common potassium channel blockers. Currently available medical procedures include ablation and the placement of implantable cardioverter defibrillators [1] .
Few studies have assessed economic outcomes on the overall CA population. Rohrbacker and colleagues [14] assessed the economic burden of CA in an employed population and found an additional $US2,897 (2008) annual cost among CA patients as compared with patients without CA. Additionally, patients with CA had significantly more sick leave and disability days compared with non-CA cohorts [14] . Although previous research has addressed specific types of arrhythmia in terms of direct medical costs (the primary focus being AF) [15] [16] [17] [18] [19] [20] , limited research exists regarding the overall impact of CA as a whole on population-based economic outcomes and resource use. In addition, previous research has indicated that health disparities exist in the use of cardiac diagnostic and therapeutic procedures [21, 22] . Working to eliminate gaps in access to care, especially in vulnerable populations such as those with CA, is an issue that has received little attention. Among the Medicare beneficiaries and the dual eligible beneficiaries, studies have found that non-Hispanic blacks and Hispanics had significantly lower use of and spending overall on medications and disease-specific medications such as antihypertensive medications and antiarrhythmic agents [23] [24] [25] [26] . It is important to identify gaps in access to care and expenditures to implement healthcare policy that improves patient outcomes and quality of life, while attempting to reduce cost. Therefore, the primary objective of this study was to examine a cohort of patients with CA in the US and identify predictors of cost of care and healthcare resource use amongst subpopulations based on age, gender, race, and the use of anti-arrhythmic agents.
Methods
This retrospective database analysis used data sets from the US Agency for Healthcare Research and Quality Medical Expenditure Panel Survey (MEPS) household component for the years [2004] [2005] [2006] [2007] [2008] [2009] . The MEPS comprises three distinct but relevant surveys: the household component, medical provider component, and insurance component [27] . Annually, the household component consists of approximately 22,000-35,000 individuals nationwide; participants were randomly selected from those who participated in the previous year's National Health Interview Survey. The medical provider component has been used to compensate medical information, such as healthcare expenditure or medical diagnoses provided by households. The insurance component was derived from surveying private employers and governments to retrieve health insurance and cost data. MEPS household component annual data are composed of a stratified clustered random sample of non-institutionalized household persons in the US derived from the nationally representative sample of the US National Health Interview Survey in the previous year. Two separate panels are followed each year, with persons in each panel being interviewed for three rounds annually (i.e., round one to three for one panel, and round three to five for the other panel), totalizing five rounds spanning across approximately 2-2.5 years (Fig. 1) [28] . Adjustment for correlation of observations through time is not necessary when using the MEPS because: (1) each year consists of a nationally representative sample; (2) pooling produces average annual estimates; and (3) stratum and primary sampling unit variables (i.e., variables constructed to account of sample stratification and clustering in MEPS) accounted for the lack of independence across years [28] . Detailed information on demographics, insurance coverage, income, employment, healthcare access, health conditions, and prescription drugs were collected during the household interviews and stored in separate files available for public research use. Data in the current study were merged from full-year consolidated files, medical condition files, and prescribed medicine files.
This analysis included patients aged at least 18 years with a diagnosis of CA. Diagnoses codes were available in the form of clinical classification codes (CCCs) and the first three digits of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes in the MEPS. The CCCs provide a greater degree of specificity, because classifying diseases into CCC categories was based on the original five-digit ICD-9-CM codes to which patients were assigned. Thus, this study employed the CCC (CCC = 106) corresponding to CA to identify CA patients in the MEPS. A CCC code of 106 represents an aggregate of patients with the following ICD-9-CM codes: 427.0-427.2 (paroxysmal supraventricular tachycardia, paroxysmal ventricular tachycardia, and paroxysmal tachycardia), 427.31-427.32 (atrial fibrillation and atrial flutter), 427.60-427.61, 427.69 ([supraventricular] premature beats), 427.81 (sinoatrial node dysfunction), 427.89 (other specified cardiac dysrhythmias), 427.9 (unspecified CA), and 785.0-785.1 (unspecified tachycardia and palpitation). In the current study, the primary patient subgroups of interest included patients of different age, gender, race/ethnicity groups, and whether they have used anti-arrhythmic agents. CA patients exposed to the following medications were considered as using antiarrhythmic agents: quinidine, procainamide, disopyramide, lidocaine, mexiletine, tocainide, flecainide, propafenone, moricizine, acebutolol, atenolol, betaxolol, bisoprolol, carteolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, penbutolol, pindolol, propranolol, timolol, amiodarone, dofetilide, ibutilide, sotalol, diltiazem, and verapamil [29] .
Other patient characteristics considered in this analysis included insurance status (private, public only, and uninsured), urban status, geographical region, federal poverty level, years of education received, comorbidity level (using the D'Hoore version of the Charlson Comorbidity index) [30] , and disease-related risk factors of CA, including coronary heart disease [ICD The primary outcomes of interest included: (1) total annual healthcare expenditure; (2) total annual prescribed medication expenditure; (3) proportion of patients using anti-arrhythmic agents; (4) number of prescribed medications associated with their CA; and (5) proportion of patients with inpatient, outpatient, or emergency room visits associated with their CA. Expenditure-related outcomes were inflation adjusted to 2011 using the medical care component of the US consumer price index. The MEPS medical condition files have been arranged as condition-specific records, each line of record includes one ICD-9-CM and CCC code corresponding to an individual. Namely, the number of records for an individual depends on the number of diseases a person had been coded. The association between their CA and healthcare resource use was considered to be established if patients were coded a CCC of 106 and received prescribed medications or physician visits on the identical line of record.
Statistical Analysis
Generalized linear models (GLM) with binomial family and logit link were used in the following outcomes: (1) proportion of patients receiving anti-arrhythmic agents; and (2) proportion of patients that had any inpatient, outpatient, or emergency room visits. Associations between expenditure-related outcomes and patient subgroups were analyzed via GLM with gamma family and log link. Full details of the models can be found in Online Resource 1. Reference groups for categorical independent variables were selected using the subgroup with the largest patient size, or represented one extreme of the attribute. Statistical significance in regression models was presented as with and without Bonferroni correction for categorical variables with multiple subgroups to objectively analyze differences observed in multiple comparison groups. This was because a consensus regarding the necessity of adjusting for multiple comparisons in regression models has not been reached and is dependent upon the nature of study hypotheses.
Missing data were imputed using the random hotdeck imputation procedure developed by Schonlau [31] . All data analyses incorporated the clustering, stratification, and sample weighting associated with the MEPS design to generate national estimates and produce appropriate standard errors for the US non-institutionalized arrhythmic population. An alpha level of 0.05 was employed throughout all analyses, except for those under Bonferroni correction.
Results
Between 2004 and 2009, approximately 5,750,440 noninstitutionalized US civilians were estimated to experience CA (Table 1) . Among this sample, 53.8 % were aged over 65 years, 40.0 % were male, 85.3 % were non-Hispanic white, and 55.5 % were prescribed an anti-arrhythmic agent. CA patients on average incurred $US11,720 of the total direct annual healthcare cost per patient, corresponding to $US67.4 billion with respect to the total direct annual healthcare cost of CA in the US. In comparison to patients that did not receive any anti-arrhythmic agents, patients taking anti-arrhythmic agents were more likely to be aged over 65 years, be non-Hispanic white, live in rural regions, and have a greater household income. In addition, the proportion of patients taking anti-arrhythmic agents appeared to be lower in later years of the survey as opposed to earlier years.
Bivariate analyses revealed that significant differences existed between age groups, races/ethnicities, and patients that have and have not used anti-arrhythmic agents in terms of healthcare expenditures and resource use ( Table 2) . Expenditures reported are averages from 2004 to 2009 (i.e., annual estimate/total estimates across 6 years divided by six). Patients aged over 65 years had the greatest number of inpatient visits (8.4 %; p = 0.007 across age groups), and were prescribed the most number of medications (mean 2.4; p \ 0.001 across age groups). In addition, patients aged over 65 years had the highest amount of total annual healthcare expenditures ($US13,201; p \ 0.001 across age groups), highest total annual prescription medication expenditures ($US2,680; p \ 0.001 across age groups), and had the largest proportion of patients taking antiarrhythmic agents (60.5 %; p \ 0.001 across age groups).
Non-Hispanic blacks had the highest total healthcare expenditures ($US15,475; p \ 0.001 across racial groups). However, non-Hispanic whites had the highest expenditure for prescription drugs ($US2,438; p \ 0.001 across racial groups). In addition, non-Hispanic whites had the largest proportion of patients taking anti-arrhythmic agents (58.4 %; p \ 0.001 across racial groups) and had the greatest number of prescription drugs used (mean 2.1; p \ 0.001 across racial groups), which is most likely the reason for higher prescription drug expenditures.
Patients taking anti-arrhythmic agents had significantly higher expenditures on total healthcare ($US12,184 vs. $US11,142; p \ 0.001) and prescription drugs ($US2,656 vs. $US2,058; p \ 0.001), and received a greater number of prescription drugs (mean 3.2 vs. 0.5; p \ 0.001) compared with their counterparts. Additionally, while antiarrhythmic medication users had a significantly higher proportion that encountered outpatient visits (10.9 vs. 8.3 %, p = 0.046), these patients had a lower proportion of emergency department visits (6.9 vs. 10.5 %, p = 0.002) associated with their arrhythmia, respectively. Furthermore, male patients were prescribed significantly higher amounts of medications associated with their CA (mean 2.2 vs. 1.9, p = 0.027) compared with female patients. Statistically significant relationships (before Bonferroni correction) between pharmacotherapy use, age, gender, race, and study outcomes were likewise observed in multivariate regression models (Table 3 ). Compared with patients that had not taken any anti-arrhythmic agents, patients taking anti-arrhythmic agents had 1.12 times higher healthcare expenditures (p = 0.037), and a 33 % reduced risk of having any emergency department visits (p = 0.010) after adjusting for demographic variables, insurance status, year of disease, and comorbidity measures and conditions. Patients aged over 65 years had 1.36 times greater healthcare expenditures (p = 0.050), 1.64 times greater prescription drug expenditures (p \ 0.001), 3.59 times increased odds of receiving anti-arrhythmic agents (p \ 0.001), and 2.41 times greater odds to have arrhythmia-related inpatient visits (p = 0.017) as compared with patients aged between 18 and 40 years. In addition, middleaged persons had significantly higher total prescribed medication costs (p \ 0.001) and a higher proportion using anti-arrhythmic agents and having any inpatient visits (p \ 0.001) compared with young adults. In comparison to male patients, female patients had 28 % reduced odds of having inpatient stays (p = 0.047) and 26 % decreased odds to have emergency room visits (p = 0.049). Additionally, the relative risk for female patients was 1.17 times higher in total prescribed medication expenditure Non-Hispanic whites had significantly higher overall medical costs, prescribed medication costs, and had a higher proportion of patients using anti-arrhythmic agents compared with Hispanic whites and other races (all p \ 0.05). Patients with both private and public insurance had significantly greater total prescription drug costs (p = 0.014) in comparison with patients only covered by public insurance. Furthermore, privately and publicly insured patients had significantly higher total healthcare (p \ 0.001) and total prescription drug expenditures After adjusting for multiple comparisons, elderly patients remained as having significantly higher prescription drug expenditures and had a higher proportion using anti-arrhythmic agents compared with persons aged 18-40 years (Table 3) . Compared with Hispanic whites, nonHispanic whites had significantly higher prescription medication expenditures and had a significantly higher proportion of patients using anti-arrhythmic agents. In addition, a significantly higher proportion of non-Hispanic whites used anti-arrhythmic medications compared with blacks. Finally, in comparison to races other than whites or blacks, non-Hispanic whites had significantly higher total healthcare and total prescription expenditures, and had a significantly higher proportion of patients taking antiarrhythmic agents.
Discussion
Several findings were shown in this study depicting the sources of disparities in healthcare resource use regarding the US CA population. Minority populations had significantly less expenditures related to total healthcare, total prescribed medications, and anti-arrhythmic agent use related to their CA. Patients who were uninsured reported significantly less total healthcare and total prescribed medication expenditures. Geographic differences relating to inpatient and outpatient visits related to CA were also observed, with significantly higher visits occurring in the Northeast region. To the investigators' knowledge, this current study is the first to comprehensively examine costs and healthcare resource use within the US general CA population. These findings will assist healthcare professionals in understanding the burden of illness and disparities across CA subpopulations to potentially improve health outcomes and healthcare expenditures. Total healthcare and total prescription drug expenditures differed significantly across age, race, and anti-arrhythmic agent use. Patients taking anti-arrhythmic agents had significantly higher total healthcare and total prescription drug expenditures (p \ 0.001). Not surprisingly, expenditures increased as age increased. Hispanics and non-Hispanic patients had the lowest expenditures on total health and prescriptions. Rohrbacker et al. [14] reported that the overall adjusted mean cost of patients with arrhythmia was approximately $US5,871 annually and patients with AF had an average annual cost of $US6,961 when accounting for healthcare, prescription drug, sick leave, short-and long-term disability, and workers compensation expenditures. Results from this study, with slightly higher prescription drug expenditures, are consistent with the findings of Rohrbacker et al., and indicate that CA represents a substantial burden to patients, providers, and the healthcare system.
The current study found that female patients were significantly less likely than male patients (p \ 0.05) to be on prescription drugs associated with their CA. A possible contributing factor could be the fact that women experience more adverse drug events taking anti-arrhythmic agents than men. Previous research has also demonstrated that certain anti-arrhythmic agents (e.g., sotalol or dofetilide), if used in female patients, may be at higher risk of QT prolongation and torsades de pointes [32] . Women, on average, have higher resting heart rates, shorter sinus node recovery times after overdrive pacing, and longer corrected QT intervals compared with men [26] . Additionally, women taking anti-arrhythmic agents (particularly amiodarone) for CA also have an increased risk of bradyarrhythmias [33] . Essebag et al. found that women are at a greater risk versus men (OR 3.86; 95 % CI 1.70-8.75) of bradyarrhythmia and replacement of a permanent pacemaker when prescribed amiodarone [34] .
Minority races including blacks, Hispanic whites, and other races were found to be significantly less likely to be exposed to anti-arrhythmic agents and to be prescribed fewer medications associated with their CA, and Hispanics had less total direct healthcare expenditure than non-Hispanic whites (p \ 0.001). A potential reason for this difference may be attributed to access or lack thereof to health insurance. For example, Hispanics account for approximately 13 % of the US population [35] yet only 25 % have access to health insurance. A lack of insurance in these minority populations produces negative health outcomes, including less access to preventive care; high rates of emergency department use; avoidable hospitalizations; later-stage diagnosis of cancer; and the inability to receive prescription medications [36] . Research has shown that minority Medicare beneficiaries take fewer medications and spend less on prescription medications [26] . Gaskin et al. [26] performed a study that examined the impact of race and ethnicity on spending for and use of prescription medications and found that Black and Hispanic Medicare beneficiaries had lower total spending and out-of-pocket expenditure annually ($US330.10 and $US343.60), which both proved to be statistically significantly (p \ 0.05) lower than non-Hispanic whites ($US473.80). Results from this study are consistent with these findings and suggests that differences in population characteristics could explain the significant difference in spending between minority populations and non-Hispanic whites. For example, immutable and unobserved factors such as poor patientphysician communication, patients' preferences, and physicians' prescribing habits can hinder improvement in socioeconomic status and insurance coverage [26] .
Future policy should aim to eliminate gaps in access to care. Healthy People 2010 was evaluated in a recent study and, of the 169 objectives for which data for various racial and ethnic groups were available, there were no changes in disparities for 111 (69 %) objectives [37] . Healthy People 2020 proposes similar goals of eliminating health disparities, and it is essential to understand disparity implications of policies, laws, and regulations to ensure that they are reduced and eventually eliminated in the coming decades [38] .
Additionally, the current study found that the proportion of CA patients with inpatient visits was significantly higher in elderly male patients. These results differ from those of Khairallah et al. [39] who found that approximately 44.8 % of hospitalized patients with arrhythmia were men; however, they found that men were significantly (p \ 0.0001) more likely to die during hospitalization for arrhythmia as compared with women (OR 1.06 95 % CI 1.05-1.06). Hospital care constitutes the greatest and most variable component of overall costs concerning patients with AF [16] . In addition, these patients have higher cardiovascularrelated healthcare costs following initial diagnosis [16] . Although the extrapolation of findings in AF patients to the general CA population may not be guaranteed, it is important to focus on conducting health outcomes research and establishing health policies aimed at reducing the burden related to inpatient hospital resource use in these subpopulations.
It should be noted that geographic region was also a significant predictor of inpatient and outpatient visits related to CA. Compared with the Northeast region, patients who resided in the Midwest were significantly less likely to have inpatient visits related to their CA. Furthermore, patients who resided in the South and West regions of the US were significantly less likely to have outpatient visits related to their CA compared with those in the Northeast. Ideally, a diagnosis of a chronic condition would be solely an attribute of the patient; however, a recent study of Medicare patients indicated an association between regional diagnostic practice and the number of diagnoses made, with individuals living in high-practice intensity regions to have approximately twice as many diagnoses than those living in lowpractice regions [40] . Additional work has indicated evidence that hospital use varies substantially across and within states [41] [42] [43] . While this is not necessarily a limitation to the study, results regarding geographic region should take these variations into account.
This study was subject to several limitations. First, the burden of illness in subtypes of CA such as AF cannot be examined because of data restrictions. Additionally, the database records a maximum of three diagnosis codes per medical record per person. Thus, there may be a small proportion of CA patients that cannot be identified. An additional limitation is that medication adherence and disease severity specifically pertaining to CA could not be measured. Relationships found between patient characteristics and economic outcomes may be confounded by disease severity or medication adherence, as patients with greater disease severity or poorer adherence were likely to have greater healthcare costs and resource use. Hence, study findings may partially be attributable to subgroups that had substantially different disease severity or medication adherence. It should be also noted that healthcare expenditures estimated in this study accounted for all medical expenditures associated with a patient with arrhythmia; such expenses cannot be solely attributable to CA and did not account for indirect costs. Furthermore, the relationship between outcomes and determinants assessed in the regression models were based on cross-sectional data. Thus, causal relationships cannot be unanimously identified.
Conclusion
This exploratory study identified disparities in healthcare resource use and economic burden from 2004 to 2009 in specific subpopulations among the CA population.
Minority populations, individuals who are 125-400 % below the federal poverty level, and the uninsured had significantly less health expenditures, total prescribed medications, and anti-arrhythmic agent use related to their CA. Future studies are encouraged to apply results from the current study to form hypotheses to assess the causal factors and potential resolutions toward the disparities, to lessen the economic burden and disparities in healthcare resource use in this patient population. Future policymaking decisions must consider all the available evidence on the use of healthcare resources among all patient subgroups to ensure that none of the policy provisions perpetuate racial/ethnic disparities. To improve outcomes in this patient population, continued work to both study and address differences in the quality and access to care is required.
